Tag: <span>macular degeneration</span>

Home / macular degeneration
Post

Common diabetes drug shows promise for treating macular degeneration

October 1, 2024 by University of Chicago Medical Center Age-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over 50 in the United States. According to estimates from the National Eye Institute, approximately 11 million people in the U.S. are affected by some form of AMD, and that number...

Diagnosed with macular degeneration? Here’s what you need to know
Post

Diagnosed with macular degeneration? Here’s what you need to know

by Dennis Thompson Age-related macular degeneration can lead to vision loss in seniors, but new therapies have offered fresh hope for preserving eyesight later in life, eye experts say. These cutting-edge therapies benefit both the dry and wet types of age-related macular degeneration (AMD), says the American Society of Retina Specialists (ASRS). Eleven million people...

Does more outdoor light at night help cause macular degeneration?
Post

Does more outdoor light at night help cause macular degeneration?

by Ernie Mundell As levels of nighttime artificial outdoor light rise, so do the odds for a leading cause of vision loss, age-related macular degeneration (AMD). South Korean researchers found that people living in areas of that country with the highest levels of streetlights and other artificial light had more than double the odds for...

Post

QUANTUM CHEMISTRY PROTECTS AGAINST MACULAR DEGENERATION

Age-related macular degeneration is the leading cause of vision loss in Western countries. The condition, a deterioration of central vision, begins when droplets of lipids and proteins called lipofuscin accumulate in the retina and damage cells. Effective treatments for age-related macular degeneration (AMD) are not available and it remains unclear how healthy eyes prevent this...

Post

An antibody-based drug triggers rare inflammatory eye problems in macular degeneration patients

by Delthia Ricks , Medical Xpress Neutralizing and non-neutralizing ADAs in complex with brolucizumab. A structural model of a complex comprised of one neutralizing anti-brolucizumab antibody in blue, and two non-neutralizing antibodies in light yellow. Brolucizumab is shown in gray, with the VEGF-A-binding CDRs highlighted in magenta. ADA, anti-drug antibody; CDR, complementarity-determining region; VEGF-A, vascular...

Post

Age-related macular degeneration a risk factor for COVID-19 infection, severe disease

BOSTON UNIVERSITY SCHOOL OF MEDICINE (Boston)— Recent evidence has emerged to suggest that age-related macular degeneration (AMD) is a clinical risk factor for increased risk for infection and mortality. AMD has been reported to confer higher risk of severe complications of SARS-CoV-2 infection, including respiratory failure and death (25 percent), a risk which is higher than Type 2...

New gene therapy shows promise for treating age related macular degeneration
Post

New gene therapy shows promise for treating age related macular degeneration

by  Trinity College Dublin Rescue of ARPE19 cells insulted with NaIO3. 5.0 × 104 ARPE19 cells were transduced with AAV2/8-ophNdi1 5-h post-seeding; MOI = 5.4 × 105 (K–O). Twenty-eight-hour post-transduction cells were insulted with 5-mM NaIO3 (F–O) and 24-h post-insult cells were fixed and stained with Phalloidin-iFluor 647 (F-actin, light blue), and CPN60 (mitochondrial marker, magenta) and 8-OHdG-Alexa Fluor 488 (oxidative stress marker, green) immunocytochemistries;...

Genetic clues to age-related macular degeneration revealed
Post

Genetic clues to age-related macular degeneration revealed

Better diagnosis and treatment of the incurable eye disease age-related macular degeneration is a step closer, thanks to the discovery of new genetic signatures of the disease. Fluorescent imaging of retinal pigment epithelium. Image credit: Dr Grace Lidgerwood / Garvan Institute Scientists from the Garvan Institute of Medical Research, the University of Melbourne, the Menzies Institute for...

  • 1
  • 2
  • 4